{"id":"https://openalex.org/G2012452524","display_name":"Mch20: Detecci\u00f3n de da\u00f1o hep\u00e1tico a trav\u00e9s de la orina","description":"La sociedad se enfrenta a la epidemia de las patolog\u00edas hep\u00e1ticas, extendi\u00e9ndose y afectando a 1700M de personas si consideramos solamente la enfermedad del h\u00edgado graso no alcoh\u00f3lica (EHGNA). La gesti\u00f3n de las patolog\u00edas, frecuentemente asintom\u00e1ticas, presenta un desaf\u00edo ante la falta de an\u00e1lisis rutinarios eficaces. La determinaci\u00f3n de las transaminasas en suero es el m\u00e9todo empleado, el cual se puede hacer por rutina debido a su bajo coste pero presenta una tasa de falsos negativos del 80%. Aunque se hacen 30M de an\u00e1lisis al a\u00f1o pocos de ellos ofrecen informaci\u00f3n \u00fatil. Por otro lado el gold-standard consiste en biopsia: elevado coste, necesario personal especializado y un riesgo para el paciente. Los m\u00e9todos alternativos que se est\u00e1n desarrollando presentan la limitaci\u00f3n del coste, por lo que no pueden ser usados de rutina. La carga socioecon\u00f3mica de la EHGNA se ha estimado en alrededor de 2M de muertes al a\u00f1o y 65M \u20ac solamente en Europa y EEUU.  Para hacer frente al problema en el Liver Disease Lab se ha caracterizado la presencia de un biomarcador en prina que aparece cuando el da\u00f1o hep\u00e1tico ocurre, incluso en las etapas m\u00e1s tempranas de la enfermedad. La proof-of-concept ha prevalidado su presencia en alrededor de 300 muestras animales y humanas. En base a su detecci\u00f3n mediante un anticuerpo espec\u00edfico, vamos  a desarrollar un point-of-care (PoC) que permitir\u00e1 identificar patolog\u00edas hep\u00e1ticas con una sola muestra de orina de manera no invasiva, f\u00e1cil de usar y efectiva. Consistir\u00e1 en un ensayo de flujo lateral basado en una membrana de nitrocelulosa y un anticuerpo conjugado a esferas fluorescentes, permitiendo incluso cuantificar la presencia del marcador. Mch20 puede tener un gran impacto en la gesti\u00f3n cl\u00ednica, mejorando sobre todo la estratificaci\u00f3n de pacientes.","funder_award_id":"DTS20/00138","funder":{"id":"https://openalex.org/F4320334923","display_name":"Instituto de Salud Carlos III","doi":"10.13039/501100004587"},"funded_outputs":["https://openalex.org/W3124838191","https://openalex.org/W3136659231","https://openalex.org/W3155450006","https://openalex.org/W3195618009","https://openalex.org/W3199044409","https://openalex.org/W4211232972","https://openalex.org/W4212806090","https://openalex.org/W4225249157","https://openalex.org/W4281789951","https://openalex.org/W4285091573","https://openalex.org/W4285741554","https://openalex.org/W4287076463","https://openalex.org/W4287112070","https://openalex.org/W4287118347","https://openalex.org/W4287118481","https://openalex.org/W4287118698","https://openalex.org/W4287388110","https://openalex.org/W4289637682","https://openalex.org/W4292262037","https://openalex.org/W4297942473","https://openalex.org/W4297942968","https://openalex.org/W4297943370","https://openalex.org/W4297943446","https://openalex.org/W4297943594","https://openalex.org/W4297943776","https://openalex.org/W4309852665","https://openalex.org/W4311505931","https://openalex.org/W4321500012","https://openalex.org/W4327546837","https://openalex.org/W4377024342","https://openalex.org/W4384133357","https://openalex.org/W4385547623","https://openalex.org/W4391684203","https://openalex.org/W4392969780","https://openalex.org/W4394614816","https://openalex.org/W4397047691","https://openalex.org/W4400683867","https://openalex.org/W4404444964","https://openalex.org/W4410117574","https://openalex.org/W4412986547"],"funded_outputs_count":40,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":94600.0,"currency":"EUR","amount_usd":116083.66,"amount_usd_basis":"daily_rate","recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"infrastructure","funder_scheme":null,"start_date":"2021-01-01","end_date":"2022-12-31","start_year":2021,"end_year":2022,"landing_page_url":"https://portalfis.isciii.es/proyecto?idProyecto=DTS20/00138","doi":null,"provenance":"portal_fis_isciii","lead_investigator":{"given_name":"Maria","family_name":"Luz Martinez Chantar","orcid":null,"role_start":null,"affiliation":{"name":"CIC BIOGUNE","country":"ES","ids":null}},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G2012452524","primary_topic":null,"topics":null,"institution_awarded":[{"id":"https://openalex.org/I4210112728","display_name":"CIC bioGUNE","ror":"https://ror.org/02x5c5y60","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210112728"]}],"updated_date":"2026-10-16T03:01:01.000Z","created_date":"2026-07-13T04:51:35.000Z"}